“Marty is an accomplished leader who has made many vital contributions to our development efforts,” said Reenie McCarthy, Stealth’s CEO. “In addition to leading our pharmaceutical sciences and technical operations initiatives, including in connection with our upcoming NDA submission, associated launch planning, and ongoing work to develop an intravitreal injection for elamipretide for dry AMD, Marty has also made great strides progressing our pipeline of mitochondria targeted therapeutics. Under his leadership, we’ve generated promising preclinical data for SBT-272 and the SBT-550 series in various neurological disease models. I am pleased to announce Marty’s well-deserved promotion and am confident that he will continue to drive new levels of scientific excellence as we advance Stealth’s development pipeline.”
To read the full article, click here.